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most associated SNP at one locus affects splicing and expression of UBASH3A, with the 
protective allele (C) predicted to cause non-stop mediated mRNA decay and lower 
expression of UBASH3A. Although 75% of PSC patients have comorbid inflammatory 
bowel disease (IBD), our data suggest that the genome-wide genetic correlation (rG) 
between PSC and ulcerative colitis (UC) (rG=0.29) is significantly greater than that between 
PSC and Crohn’s disease (CD) (rG=0.04) (P=2.55×10−15). Importantly, UC and CD are 
genetically more similar to each other (rG=0.56) than either is to PSC (P<1.0×10−15). Our 
study represents a significant advance in our understanding of the genetics of PSC.
Primary sclerosing cholangitis affects around 1 in 10,000 individuals of European ancestry 
and is characterised by chronic inflammation and stricturing fibrosis of the biliary tree1. 
There remains no effective medical therapy and the majority of patients require orthotopic 
liver transplantation owing to the progressive nature of the disease2. PSC is highly comorbid 
with IBD, which is ultimately diagnosed in around 75% of patients. The clinical presentation 
of IBD in PSC is most often consistent with UC (~80%), but CD (~15%) and indeterminate 
forms of IBD (~5%) do occur in some patients. Time of disease onset and expression of the 
IBD phenotype in PSC is variable, with an overall trend toward IBD preceding PSC and 
milder but more extensive intestinal inflammation (pancolitis) compared to classical UC or 
CD3,4 This tendency, along with other clinical and epidemiological differences, has led to 
the proposal that IBD in the context of PSC (PSC-IBD) should be considered a disease 
entity separate from both UC and CD. Elevated risk of PSC and UC in first-degree relatives 
of PSC patients indicates a strong genetic component to PSC susceptibility and suggests the 
presence of shared genetic risk factors between PSC and UC5,6. However, the genetic 
relationship between PSC and UC/CD/IBD remains poorly defined because the low 
prevalence of PSC has precluded familial studies. Large-scale association studies have 
identified sixteen loci, including the HLA locus, underlying PSC risk7–12. Here, we 
undertake the largest genome-wide association study of PSC to date to identify novel PSC 
risk loci and enable us, for the first time, to estimate the genome-wide genetic correlation 
between PSC and the common forms of IBD.
Following quality control (Supplementary Tables 1 and 2, Supplementary Figs. 1–3) and 
imputation using reference haplotypes from the 1000 Genomes (Phase III) and UK10K 
projects13,14, we tested 7,891,602 SNPs for association in a sample of 2,871 PSC cases and 
12,019 population controls using a linear mixed model to account for population 
stratification (Online Methods, Supplementary Tables 1 and 2). Genome-wide summary 
statistics are available from the International PSC Study Group website (see URLs). Forty 
SNPs were tested for association in an independent cohort of 1,925 PSC cases and 7,936 
population controls (Online Methods, Supplementary Table 3), including 24 SNPs with P < 
5×10−6 in the GWAS that are located outside of known PSC loci. We used an inverse-
variance weighted fixed effects meta-analysis, implemented in METAL15, to test the 
evidence of association across the GWAS and replication cohorts combined and identified 
four new genome-wide significant loci with P < 5.26 × 10−3 in the replication study and P < 
5 × 10−8 in the combined meta-analysis (Table 1, Supplementary Table 4, Supplementary 
Fig. 4). One of the newly associated loci, tagged by rs80060485 (3:g.71153890T>C) in 
FOXP1, is associated with immune-mediated disease for the first time. The three other 
newly associated PSC loci (implicating CCDC88B, CLEC16A and UBASH3A) are in high 
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linkage disequilibrium (LD), defined as (r2 > 0.8) with variants significantly associated to 
other immune-mediated diseases (Supplementary Table 5). We found consistent evidence of 
association at fifteen of the sixteen previously established PSC loci and now consider 19 
regions of the genome to be associated with PSC risk (Supplementary Table 4, 
Supplementary Fig. 4).
All SNPs in high LD (r2 > 0.8) with the most associated SNP at each PSC locus were 
evaluated for potential function using SIFT16 and PolyPhen 217, the Genome Wide 
Annotation of Variants (GWAVA) online tool18, and a number of eQTL databases (Online 
Methods, Supplementary Tables 6–8). One of the new PSC risk variants (rs1893592, 21:g.
43855067A>C) is the most strongly associated eQTL of UBASH3A, a gene involved in 
regulation of T-cell signalling, in two whole blood-based analyses19,20 and a B-cell only 
study21. The SNP is located three bases downstream of the 10th exon of UBASH3A, within 
the splice consensus sequence, and was reported as a splice-QTL in a recent RNA 
sequencing study19. The C allele, which is associated with reduced risk of PSC and has a 
frequency of 27.8% in our controls, disrupts the conserved 5′ splice donor sequence at this 
position in vertebrate introns, which is typically A (71% of sites) or G (24% of sites)22. The 
predicted consequence of this change is partial retention of the downstream intron possibly 
leading to non-stop mediated decay. Reanalysis of the gEUVADIS RNA-seq data23 revealed 
that this SNP was the most strongly associated with increased intron expression (P = 
2×10−16, Supplementary Figure 5), with the PSC protective allele causing intron 10 to be 
retained in the UBASH3A mRNA. Further work is required to determine whether carrying 
the C allele at this SNP decreases UBASH3A protein levels and if this is the causal 
mechanism behind the reduced risk of PSC, celiac disease and rheumatoid arthritis 
(Supplementary Table 5). In addition, another variant within the UBASH3A gene 
(rs11203203, 21:g.43836186G>A) that is in low-LD (r2 = 0.12) with rs1893592 has been 
associated with vitiligo24 and type-1 diabetes25, further supporting the role of UBASH3A in 
immune-mediated disorders. We were unable to identify any current drugs targeting 
UBASH3A (Supplementary note).
To enable us to address the genetic relationship between PSC and IBD we obtained 
association summary statistics from the International IBD Genetics Consortium for 20,550 
CD cases, 17,647 UC cases and 48,485 controls of European ancestry26. Across each of the 
eighteen non-HLA PSC risk loci we used a Bayesian test of colocalisation27 to identify loci 
with strong evidence (posterior probability > 0.8) of either shared or independent causal 
variants between pairs of traits (Online Methods, Supplementary Table 9). Four of the 
eighteen PSC risk loci have not been associated at genome-wide significance with IBD 
(BCL2L11, FOXP1, SIK2 and UBASH3A) although the lead SNPs at two of these loci 
(rs72837826 – BCL2L11 and rs1893592 – UBASH3A) did demonstrate strong evidence for 
colocalisation (posterior probability > 0.8) and suggestive evidence of association (P < 10−4) 
in the UC cohort (Supplementary Table 9, 10). Of the fourteen PSC loci that had been 
previously associated with IBD (UC, CD or both), four demonstrated strong evidence that 
the causal variant is independent from that in UC and CD (IL2RA, CCDC88B, CLEC16A 
and PRKD2), a finding supported by the low linkage disequilibrium (r2 < 0.2) between the 
lead SNPs in PSC and UC/CD at these loci (Supplementary Tables 9 and 10). Thus, even for 
highly comorbid diseases, significant association to the same region of the genome will not 
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always be driven by a shared causal variant. This supports similar observations for other 
related phenotypes such as psoriasis versus psoriatic arthritis28,29. Six of the fourteen loci 
associated with PSC and IBD displayed strong evidence of a shared causal variant with UC, 
CD or both (MST1, IL21, HDAC7, SH2B3, CD226 and PSMG1) (Figure 1, Supplementary 
Tables 9 and 10). We further tested these six SNPs for evidence of heterogeneity of effect 
using Cochran’s Q test (Online Methods). Four showed significantly increased effect size in 
PSC relative to both UC and CD (MST1, IL21, SH2B3 and CD226) (P < 2.78×10−3) with an 
additional locus (PSMG1) showing significantly increased effect size relative to CD only 
(Figure 1). Simulation studies showed that the observed heterogeneity of effect is unlikely to 
be driven by the large difference in sample size between the PSC and UC cohorts (Pempirical 
< 3.00×10−4 at all four SNPs) (Supplementary Note). We did not detect evidence of 
heterogeneity of effect between PSC patients expressing different IBD phenotypes (PSC-
UC, PSC-CD or PSC-NoIBD) (Supplementary Fig. 6). However, our power to detect 
significant heterogeneity of effect between these PSC subphenotypes was limited by sample 
size (Supplementary Table 11).
While the much larger size of the UC and CD cohorts gives us power to investigate the 
effects of PSC risk SNPs in IBD, the PSC cohort is underpowered to do the reverse. Thus, to 
clarify the pairwise genetic correlation between PSC, UC and CD we obtained genome-wide 
individual level genotype data from the International IBD Genetics Consortium for 6,247 
CD cases, 6,686 UC cases and 34,393 population controls of European descent26 and used 
GCTA to estimate genome-wide genetic correlations (rG) using a bivariate linear mixed 
model30,31 (Online Methods, Supplementary Note). This analysis quantified the SNP-
heritability (h2SNP) of PSC as 0.148 (95% CI: 0.135–0.161), and showed that in the context 
of common genetic variation, PSC is significantly more related to UC (rG = 0.29) than CD 
(rG = 0.04) (P = 2.55×10−15) (Figure 2), consistent with the clinical phenotype most often 
observed in PSC-IBD patients. Moreover, the genetic correlation between UC and CD (rG = 
0.56) is significantly greater than that between PSC and either UC or CD (P < 1.0×10−15). 
Due to a lack of data regarding the PSC status of individuals in the UC and CD cohorts we 
could not remove the approximately 5% of patients we would expect to have comorbid PSC. 
This suggests that, while our estimates of the genome-wide genetic correlation between PSC 
and both UC and CD may seem surprisingly low, these are likely slight overestimates of the 
true genetic correlation between the diseases. We validated the GCTA co-heritability 
estimates using a summary statistics-based genetic correlation analysis (LD score 
regression32), and found support for the reported genetic relationships (i.e. rGCD.vs.UC = 
0.68 > rGPSC.vs.UC = 0.39 > rGPSC.vs.CD = 0.09) (Supplementary Figure 7). The low 
genome-wide genetic correlation between PSC and the IBDs is also supported by known 
differences in HLA risk alleles11,33 and our discovery that PSC has both independent causal 
variants and shared causal variants of heterogeneous effect size compared to both UC and 
CD. The analyses presented in this study, based on common genetic variants (MAF > 1%), 
suggest functional studies in both the biliary tree and intestinal tract are required if we are to 
understand the biological consequences of PSC associated genetic variants, whether or not 
they are shared with IBD.
While it is clear that a substantial component of the genetic architecture of PSC is not shared 
with either CD or UC, our data also show that shared genetic risk factors do certainly exist 
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and likely play some role in disease comorbidity. However, under a purely additive genetic 
liability threshold model, the genetic covariance between the two diseases would need to be 
greater than 0.76 to fully explain the fact that 60% of PSC cases have comorbid UC 
(Supplementary Figure 8). In contrast, the observed genetic correlation (rG = 0.29) would 
generate a PSC-UC comorbidity rate of only 1.6% under this model. This demonstrates that 
the observed extent of comorbidity between PSC and UC is not fully explained by shared 
additive genetic effects of common variants and that other factors must play a role, such as 
shared environmental effects or shared rare variants not captured by our GWAS and 
imputation data.
In summary, we have performed the largest genome-wide association study of PSC to date 
and identified four new PSC risk loci. We now consider 23 regions of the genome to be 
associated with disease risk, including four loci only recently associated with PSC in a 
cross-disease meta-analysis34. One of our new associations suggests that decreased 
UBASH3A is associated with a lower risk of PSC through a common NMD variant. We 
have also shown that, even for highly comorbid phenotypes such as PSC and IBD, 
significant association to the same region of the genome will not always be driven by a 
common causal variant. Furthermore, by conducting genome-wide comparisons with CD 
and UC we have, for the first time, shown that the comorbid gastrointestinal inflammation 
seen in the majority of PSC patients cannot be fully explained by shared genetic risk. Thus, 
the biliary and intestinal inflammation seen specifically in PSC should be studied to advance 
our understanding of the disease and improve clinical outcome for patients with this 
devastating disorder.
Online Methods
Ethical Approval
The ethics committees or institutional review boards of all participating centers approved the 
studies and the recruitment of participants. Written informed consent was obtained from all 
participants.
GWAS cohort
Cohorts and genotyping—731 PSC cases and 3,202 population controls from 
Scandinavia and Germany were ascertained and genotyped using the Affymetrix Genome-
Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA) at three different centers7. 
A cohort of 1,227 UK PSC cases was recruited from across more than 150 UK National 
Health Service Trusts or Health Boards, including all transplant centers in the UK, by the 
UK-PSC consortium. A cohort of 904 US PSC patients were enrolled in the PSC Resource 
of Genetic Risk, Environment and Synergy Studies (PROGRESS), a multicenter 
collaboration between eight academic research institutions across the US and Canada. 
PROGRESS ascertained additional DNA samples from established PSC cohorts from 
Canada (N=259) and Poland (N=43). The UK and US GWAS cohorts were genotyped using 
the Illumina HumanOmni2.5-8 BeadChip (Illumina, San Diego, CA, USA) and called using 
the GenCall algorithm implemented in GenomeStudio. UK samples were genotyped at the 
Wellcome Trust Sanger Institute (Hinxton, UK) and the US samples at the Mayo Clinic 
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Medical Genome Facility (Rochester, MN, USA). A diagnosis of PSC was based on 
standard clinical, biochemical, cholangiographic and histological criteria35, with exclusion 
of secondary causes of sclerosing cholangitis. Commonly accepted clinical, radiological, 
endoscopic and histological criteria were also used for diagnosis and classification of IBD36. 
Genetic data from 12,595 individuals genotyped on the Illumina HumanOmni2.5-4v1 array 
(Omni2.5-4) as part of The University of Michigan Health Retirement Study were 
downloaded from the Database of Genotypes and Phenotypes (dbGaP37). Genotyping was 
performed at the Center for Inherited Disease Research (CIDR) and genotypes called using 
GenomeStudio version 2011.e, (see the HRS website for more details).
Quality control—All SNPs were aligned to NCBI build 37 (hg19). Genotype data were 
quality controlled independently across 6 batches defined by genotyping centre (AffySF: N = 
2,205, AffyHZ: N = 1,256; AffyAB: N = 472; IlluminaWTSI: N= 1,227;IlluminaMAYO: N= 
1,206; IlluminaCIDR: N = 12,595). Initially, SNPs out of Hardy-Weinberg equilibrium 
(HWE: P < 1×10−6) in controls (excluding those in the HLA region) or with a call rate less 
than 80% were removed. SNPs failing in at least one batch were removed from all cohorts 
genotyped using the same chip. For sample QC, individuals whose sex determined using the 
X chromosome homozygosity rate (F) and Y chromosome call rate differed from that in our 
patient database (or could not be genetically determined, F or Y-chromosome call rate 
between 0.3–0.7) were removed. Next, Abberant38 was used to identify samples with 
outlying heterozygosity or genotype call rate. Samples with a call rate less than 90% for an 
individual chromosome were also removed. A set of 82,085 independent SNPs (pairwise r2 
<0.2) genotyped on all arrays was identified for the purpose of estimating sample relatedness 
and ancestry, excluding SNPs that a) were within regions of high linkage disequilibrium, b) 
had a MAF < 10% or c) were A/T or C/G SNPs. Pairwise identity by descent was estimated 
for all individuals in the study using PLINK, and the sample with the lowest genotype call 
rate was removed for all pairs with IBD > 0.9. Both samples were excluded if case/control 
status was discordant between duplicates. To maximize power to detect association, related 
samples (0.1875 < IBD < 0.9) were retained and a mixed model used for association testing. 
Sample ancestry was inferred via principal components analysis implemented in 
EIGENSTRAT39. Population principal components were calculated using genotype data 
from the CEU, YRI and CHB/JPT samples from the 1000 Genomes Project. Factor loadings 
from these principal components were then used to project these principal components for 
our cases and controls. Samples of non-European ancestry were identified using Aberrant38. 
The number of samples failing each QC step is shown in Supplementary Table 1. In total, 
2,871 cases and 12,019 controls passed sample QC. Next, a more thorough marker QC was 
conducted within batches by excluding, genotyping platform-wide, SNPs with a) different 
probe sequences on the Omni2.5-4 and Omni2.5-8 array, b) a call rate < 98%, c) MAF<1%, 
d) significant evidence of deviation from HWE (P < 1×10−5) in controls and e) a significant 
difference in call rate between cases and controls (P < 1×10−5), in at least one of the 
genotyping batches. Outside of the HLA region, markers only present on one of the two 
Illumina arrays were also removed. After SNP QC, 1,207,121 Omni2.5-4 SNPs, 1,215,097 
Omni2.5-8 SNPs and 528,496 Affymetrix 6 SNPs were available.
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Genotype Imputation—Only 322,807 SNPs feature on both the Affy6 and Omni2.5 
arrays so the samples genotyped on these arrays were phased and imputed separately. For 
computational efficiency, the genome was split into 3Mbp batches and those spanning the 
centromere were split and joined to the last complete batch either side of the centromere. 
Batches of less than 200 SNPs were merged with an adjacent batch. Pre-phasing was 
performed using the SHAPEIT2 algorithm40 and imputation using IMPUTE241. We used a 
combined reference panel of the 1000 Genomes Phase 1 integrated version 3 and the 
UK10K cohort, consisting of 4,873 individuals and 42,359,694 SNPs (k_hap=2,000, 
Ne=20,000). Post-imputation, SNPs with a posterior probability less than 0.9 or info score 
less than 0.5 were removed. The QC steps outlined above for directly genotyped SNPs were 
applied to the imputed genotype data. SNPs with r2 < 0.8 between directly genotyped and 
imputed genotypes were removed and phasing and imputation repeated. Following QC (as 
outlined above), a total of 7,891,602 SNPs available for association testing across 2,871 PSC 
cases and 12,019 population controls (Supplementary Table 2).
Association Analysis—A linear mixed model implemented in the MMM software42 was 
used to test association between genetic variants and case/control status. To reduce compute 
time the relationship matrix was constructed using the 82,085 quasi-independent SNPs 
previously used in the PCA. To prevent the association analyses being biased by informed 
missingness across our genotyping batches, linear mixed model association tests were 
conducted across three different batches of directly-genotyped and imputed SNPs, defined 
on their availability for only the Omni2.5 genotyped samples (N = 2,015,514), only the 
Affy6 genotyped samples (N = 114,935), or across all genotyped samples (N = 5,761,153).
Stepwise conditional regression analysis (excluding the extended MHC region) was 
undertaken in MMM to identify independent association signals (P < 5.0 × 10−6) within PSC 
associated loci. The previously reported lead SNP within each of the 15 known PSC loci was 
selected for replication, though we also took forward the most associated SNP in our study if 
it was a poor tag (r2 < 0.8) of previously reported SNP. In addition, 24 SNPs outside of 
established PSC risk loci with P < 5 ×10−6 were also included in the replication experiment. 
All cluster plots were manually inspected prior to SNP selection.
Validation and replication cohorts
Cohorts and genotyping—An independent replication cohort of 2,011 PSC cases from 
Europe and North America was ascertained following the diagnostic criteria outlined above. 
A total of 8,784 population controls of European descent were ascertained, including 515 
from the Mayo Clinic Biobank43 and 1000 from the INTERVAL study44. British and 
Canadian samples were genotyped at the Wellcome Trust Sanger Institute in Cambridge, UK 
(N = 2,366) and all other samples at the Institute of Clinical Molecular Biology in Kiel, 
Germany (N = 11,152) using the same Agena Biosciences iPLEX design. To reduce the risk 
of false-positive associations being driven by imputation errors we undertook a substantial 
validation experiment, genotyping the 40 SNPs in our replication experiment across 2,723 
cases in the GWAS study.
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Quality control—Two SNPs yielded poor genotype clusters and were removed from 
further study. Four SNPs with a call rate less than 95% or Hardy Weinberg equilibrium P < 
1.25 × 10−3 (Bonferroni correction for 40 SNPs) within controls were excluded 
(Supplementary Table 12). Samples with a call rate less than 92%, or where the genetically 
determined sex differed from that in our patient database, were removed. The sample with 
the lowest call rate in duplicate pairs was removed from duplicate pairs (IBS > 0.9) 
(Supplementary Table 3). Post-QC, one SNP had an r2 less than 0.90 between the discovery 
and validation genotyping and, following manual inspection of cluster plots, was removed 
from the replication study.
Replication and Combined association analyses—For the replication analysis, 
logistic regression tests of association were performed separately for samples from six 
geographic regions (Supplementary Table 3) using SNPTEST v2 (Marchini et al., 2007). 
Inverse-variance weighted fixed effects meta-analyses implemented in METAL16 were then 
used to a) test for association across all replication samples and b) test the evidence of 
association across the GWAS and replication cohorts combined. To classify a region as 
newly associated with PSC we required both significant evidence of association in the 
replication cohort (P < 5.26 × 10−3, Bonferroni correction for 19 one-tailed tests) and 
genome-wide significance (P < 5 × 10−8) in the combined meta-analysis.
Candidate gene prioritization
Functional annotation—All SNPs in high LD (r2 > 0.8) with lead SNPs at PSC 
associated loci were annotated for potential function using the Genome Wide Annotation of 
Variants (GWAVA) online tool19. In addition, all coding SNPs from this set were also 
annotated using SIFT16 and PolyPhen218.
Pathway analysis—To quantify the functional relationship between genes within PSC 
risk loci, we conducted a GRAIL pathway analysis. GRAIL evaluates the degree of 
functional connectivity between genes based on the extent they co-feature in published 
abstracts (we used all PubMed abstracts prior to 2006 to avoid biasing our analysis due to 
results from large-scale GWASs). All PSC associated loci were included in the analysis and 
only genes with GRAIL P < 0.05 and edges with a score of > 0.5 were included in the 
connectivity map.
Expression quantitative trait loci (eQTL)—eQTL analysis focused on published cis-
eQTLs due to the lower reproducibility caused by smaller effect sizes and context-specificity 
of trans-eQTL45. Eight eQTL datsets were included in the analysis: eQTL data from 12 
studies collated in the Chicago eQTL browser, eQTL results from 1,421 samples of 13 
different tissue types by the genotype-tissue expression (GTEx) project46, 462 
lymphoblastoid cell lines24, 922 whole blood samples20, 8,086 whole blood samples21, 
purified B cells and monocytes from 283 individuals22, activated monocytes from 432 
individuals47, and activated monocyte-derived dendritic cells from diverse populations48. 
The most significant variant-gene associations were extracted from each eQTL dataset and 
were reported as overlapping if that variant was in high LD (r2 > 0.8) with any of the lead 
SNPs in the PSC GWAS meta-analysis.
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Modelling PSC and IBD genetic risk
Association summary statistics from the European arm of the latest International IBD 
Genetics Consortium study27 were downloaded. Where available we used results from their 
combined GWAS plus Immunochip follow-up study and otherwise used those from the 
GWAS analysis. Definition of the 231 significantly associated loci as CD, UC or both (IBD) 
was taken from Liu and van Sommeren et al27. Due to the limited availability of relevant 
subphenotype data within the IIBDGC data, we were unable to identify the 3–5% of IBD 
cases that we expect to have PSC. Including these individuals as IBD cases in our 
comparisons lowers our power to detect differences between the two diseases.
Causal variant co-localisation analysis—To identify causal variants within disease 
associated loci that are shared between diseases we used a summary statistic based Bayesian 
test of colocalisation (COLOC), implemented in R28. Briefly, COLOC generates posterior 
probabilities for five different hypotheses: 1) no association to either disease, 2) association 
to disease 1 but not disease 2, 3) association to disease 2 but not disease 1, 4) association to 
both disease 1 and 2 but independent causal variants and 5) association to both disease 1 and 
2 with a common causal variant. Only SNPs present in all the cohorts (PSC, CD, UC and 
IBD) were included in the analysis and associated regions were defined as 1MB regions with 
the most associated SNP at the centre. Within each region we calculated the r2 between the 
PSC lead SNP and the SNP most associated with each of the other three diseases. Default 
priors were used for the probability of a SNP being a) associated to an individual disease 
(1×10−4) and b) causally associated to both diseases (1×10−5). This prior probability of 
colocalisation is more conservative in declaring distinct causal variants compared to a recent 
colocalisation analysis across six immune-mediated disorders49.
Heterogeneity of effects analysis—A formal heterogeneity of odds test was performed 
between PSC and IBD using the Cochran’s Q test implemented in METAL16 for all 18 PSC 
risk loci. The odds ratios and standard errors were obtained from our current PSC GWAS 
and the IIBDGC analysis27. A locus was declared to have significant heterogeneity of effects 
based on a threshold of P = 2.78×10−3 to account for multiple testing (Bonferroni correction 
applied to 5% significance threshold, N=18 tests). In order to test whether the significant 
heterogeneity of effects are due to an overestimation of effect sizes in the smaller PSC 
cohort, we undertook a simulation study which demonstrated that the observed degree of 
heterogeneity is unlikely to occur by chance (Supplementary Note).
Genetic correlation analysis—Genome-wide SNP data from 12,933 IBD cases and 
34,393 population controls of European descent was made available to us by the 
International IBD Genetics Consortium (IIBDGC). The quality control and imputation of 
these data using 1000 Genomes haplotypes has been previously described27. See 
Supplementary Note for details of the SNP and sample quality control (Supplementary Table 
13) undertaken across the IIBDGC and PSC data to ensure compatibility and remove 
duplicated individuals. Individual level genotype data for PSC, CD, UC and IBD were used 
to estimate the proportion of variance in liability explained by SNPs genome-wide under a 
multiplicative model using the linear mixed model based restricted maximum likelihood 
(REML) method implemented in the GCTA software32,50,51. Ancestry principal components 
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were calculated using genotype data from the 1000 Genomes project and were projected for 
all our cases and controls. The first twenty principals components were included as 
covariates in the linear mixed model. We assumed a prevalence of 0.0001 for PSC, 0.005 for 
CD and 0.0025 for UC. A bivariate extension of the linear mixed model31, again 
implemented in GCTA32, was used to estimate the additive covariance component and 
estimate the genetic correlation (rG) between PSC and either CD, UC, or IBD.
In addition, we undertook an alternative genetic correlation analysis that uses summary 
statistics and LD score regression33. Of the 7,458,430 SNPs that were shared between PSC 
and both IBDs, 1,102,210 HapMap3 SNPs were selected for the analysis as recommended. 
Then, pre-computed LD scores from the 1000 Genomes European data were used to run LD 
score regression to estimate genetic correlation.
Calculating comorbidity under a purely pleiotropic genetic model—Under a 
bivariate liability threshold model, where all disease risk is explained by additive genetics, 
the probability that an individual has disease 1, given that he has disease 2, is given by
where Ki is the prevalence of disease i, Ti =Φ−1(1−Ki) is the liability threshold of disease i, 
 is the heritability of disease i, rg is the genetic correlation and F(.) is the multivariate 
cumulative distribution function for normal distribution.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Odds ratios (and their 95% confidence intervals) for PSC, UC and CD across the 6 
PSC associated SNPs demonstrating strong evidence for a shared causal variant (maximum 
posterior probability > 0.8)
PSC ORs were taken from the GWAS and replication meta-analysis. UC and CD ORs were 
obtained from the latest association studies conducted by the International IBD Genetics 
Consortium26. Heterogeneity of odds tests were carried out using Cochran’s Q test. A failure 
to detect significant heterogeneity of odds does not necessarily indicate that effect sizes are 
equivalent because power to detect heterogeneity varies across SNPs.
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Figure 2. Genome-wide genetic correlation between PSC (and its subphenotypes), CD and UC
Genetic correlations (and their 95% confidence intervals) were calculated using a bivariate 
extension of the linear mixed model30 implemented in GCTA (Online Methods). PSC has a 
lower genetic correlation with both CD and UC than the two inflammatory bowel diseases 
have to each other. PSC is genetically more correlated to UC than it is to CD and this is 
consistent across the PSC subphenotypes.
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